Previous Article | Next Article 
Journal of Virology, April 1999, p. 2781-2789, Vol. 73, No. 4
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
A Second-Site Mutation That Restores Replication of
a Tat-Defective Human Immunodeficiency Virus
Koen
Verhoef and
Ben
Berkhout*
Department of Human Retrovirology, Academic
Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The
Netherlands
Received 21 September 1998/Accepted 14 December 1998
 |
ABSTRACT |
We previously constructed a large set of mutants of the human
immunodeficiency virus type 1 (HIV-1) regulatory protein Tat with
conservative amino acid substitutions in the activation domain. These
Tat variants were analyzed in the context of the infectious virus, and
several mutants were found to be defective for replication. In an
attempt to obtain second-site suppressor mutations that could provide
information on the Tat protein structure, some of the
replication-impaired viruses were used as a parent for the isolation of
revertant viruses with improved replication capacity. Sequence analysis
of revertant viruses frequently revealed changes within the
tat gene, most often first-site reversions either to the
wild-type amino acid or to related amino acids that restore, at least
partially, the Tat function and virus replication. Of 30 revertant
cultures, we identified only one second-site suppressor mutation. The
inactive Y26A mutant yielded the second-site suppressor mutation Y47N
that partially restored trans-activation activity and virus
replication. Surprisingly, when the suppressor mutation was introduced
in the wild-type Tat background, it also improved the
trans-activation function of this protein about twofold. We conclude that the gain of function measured for the Y47N change is not
specific for the Y26A mutant, arguing against a direct interaction of
Tat amino acids 26 and 47 in the three-dimensional fold of this
protein. Other revertant viruses did not contain any additional Tat
changes, and some viruses revealed putative second-site Tat mutations
that did not significantly improve Tat function and virus replication.
We reason that these mutations were introduced by chance through
founder effects or by linkage to suppressor mutations elsewhere in the
virus genome. In conclusion, the forced evolution of mutant HIV-1
genomes, which is an efficient approach for the analysis of RNA
regulatory motifs, seems less suited for the analysis of the structure
of this small transcription factor, although protein variants with
interesting properties can be generated.
 |
INTRODUCTION |
X-ray crystallography is a powerful
tool for the study of protein structure and function. However, the use
of this method is limited to proteins that crystallize. The human
immunodeficiency virus type 1 (HIV-1) Tat protein is essential for
virus replication and is a unique transcriptional
trans-activator protein. Tat is recruited to the HIV-1
long-terminal-repeat (LTR) promoter by binding to an RNA hairpin
structure termed TAR, which is formed at the 5' end of viral mRNA
(7, 13). Tat is encoded on two exons and is 86 to 101 amino
acids in length, depending on the viral isolate. The first 72 amino
acids encoded by the first exon are sufficient for the
trans-activation function (17, 22, 28, 33, 39).
In addition to its essential role in LTR transcription, Tat has been
suggested to be involved in other steps of the virus life cycle. Tat
has been reported to stimulate the process of reverse transcription
(16) and to increase the translational efficiency of HIV-1
mRNAs (8, 34, 36, 44). Despite intensive research for over
10 years, this protein of biological and medical importance has
resisted attempts to determine its structure by X-ray crystallography.
Furthermore, only limited resolution was obtained by nuclear magnetic
resonance studies (3, 14, 26).
In this study, we assess the potential of a genetic approach termed
"forced evolution" (3a) for the analysis of the Tat protein structure and function. The systematic analysis of revertant virus genomes is particularly useful for the dissection of sequence and
structural determinants of RNA signals that control a variety of steps
in the viral replication cycle (6, 21, 29, 30). In addition,
intragenic suppressor mutations in revertant HIV-1 viruses have been
described for the envelope glycoprotein (43) and the
integrase enzyme (37). The tat gene of an
infectious HIV-1 genome was mutated to introduce single amino acid
changes within the cysteine-rich trans-activation domain. We
identified several Tat-mutated viruses that exhibit a severe
replication defect in T-cell lines and primary cells (41).
In this study, some of the replication-impaired viruses were used as
starting material for long-term cultures to allow the generation of
faster-replicating revertant viruses. Such virus revertants may have
compensated for the introduced mutation by second-site changes
elsewhere in the protein, and putative interaction sites can be
revealed by this genetic technique.
Two replication-impaired HIV-1 variants with a severely inactivated Tat
protein (mutants Y26A and F32A) and two poorly replicating viruses with
a partially active Tat protein (F38W and Y47H) were cultured for a
prolonged period in multiple, independent evolution experiments. We
were able to generate fast-replicating revertant viruses in 30 cultures, of which 21 contained an additional, nonsilent mutation
within the tat gene. Of these 21 revertants, 11 first-site revertants were obtained that had replaced the mutant amino acid, either by true first-site reversion to the wild-type amino acid or by
mutation to a residue different from that observed in the wild-type Tat
protein. Several putative second-site suppressor mutations were
observed in Tat, but only one demonstrated improved Tat activity in
transient-transfection assays.
The Y26A Tat mutant regained partial activity by inclusion of the Y47N
change, and a concomitant increase in virus replication was measured.
Surprisingly, when this second-site change was introduced as an
individual mutation in the wild-type Tat protein, it improved the
activity of this protein to merely 200%. Thus, the Y47N mutation represents a more general manner to make a more active Tat protein, which argues against a specific amino acid contact between Tat positions 26 and 47. We will discuss potential reasons for the absence
of a 200% active Tat protein in natural HIV-SIV isolates. The other
second-site mutations did not improve the Tat
trans-activation function but could have restored a putative
additional function of Tat in the viral life cycle. We tested this for
some of the revertants in virus replication studies, but none of the
revertants demonstrated enhanced fitness compared with the
corresponding mutants. We propose that these second-site mutations
represent either natural Tat variation or changes that were linked to
mutations elsewhere in the HIV-1 genome that did contribute to the
reversion event. These results indicate that the systematic analysis of mutant-revertant viruses is not a particularly efficient method for
gaining insight into the structure of this small, regulatory viral
protein, although this method yielded some Tat variants with intriguing properties.
 |
MATERIALS AND METHODS |
Cell culture, virus infections, and DNA transfection.
The
construction of the Tat-mutated HIV-1 LAI proviral clones was described
previously (41). The Y47H mutant that was used in this study
corresponds to the Y47H2 mutant (codon CAC) described in that study.
SupT1 and C8166 T cells were cultured in RPMI medium supplemented with
10% fetal calf serum, 100 U of penicillin per ml and 100 µg of
streptomycin per ml and transfected by means of electroporation
(11). For the selection of revertant viruses in forced
evolution experiments, we used 30 µg of mutant pLAI plasmid to
transfect 5 × 106 SupT1 or C8166 cells. One day after
transfection, the cells were split 1 into 6 and divided over a 6-well
culture plate to obtain independent reversion events. These cells were
cultured for up to 160 days after transfection, splitting the culture 1 into 10 every 4 days. Once virus spread was evident by the appearance of syncytia, we passaged the virus-containing culture supernatant at
the peak of infection onto fresh T cells. We initially used 100 µl of
cell-free supernatant to infect a 5-ml T-cell culture, but this amount
was gradually reduced to 0.1 µl. At regular intervals, infected cells
were taken from the culture and frozen for subsequent analysis of the
proviral DNA.
Transient transfection of SupT1 cells for chloramphenicol
acetyltransferase (CAT) assays or viral replication studies has been
described previously (41). C33A cells were grown in Dulbecco modified Eagle medium medium with supplements as described earlier (11) and transfected by the calcium phosphate precipitation method. Briefly, cells were grown to 60% confluency in 60-mm culture dishes. Unless indicated otherwise, we used 1 µg of LTR-CAT reporter plasmid and 100 ng of pTat in transient transfections. The total amount
of DNA in the transfection was adjusted to 6 µg with pcDNA3 carrier
plasmid in 132 µl of H2O, mixed with 150 µl of 50 mM
HEPES (pH 7.1)-250 mM NaCl-1.5 mM Na2HPO4 and
18 µl of 2 M CaCl2, incubated at room temperature for 20 min, and added to the culture medium (4 ml). The cells were washed the
next day, and fresh culture medium was added.
CAT assays and CA-p24 ELISA.
Transiently transfected cells
were collected by trypsinization (adherent cell types) or
centrifugation (nonadherent cell types) at 3 days posttransfection. CAT
assays were performed on whole-cell lysates by using the
phase-extraction protocol (32). The CA-p24 level in
cell-free supernatant from virus cultures was determined by antigen
capture enzyme-linked immunosorbent assay (ELISA) (2).
Proviral DNA analysis and cloning of revertant sequences.
The Tat expression vector pTat used in this study is a derivative of
pcDNA3-Tat (41). A 61-bp
HindIII-HindIII fragment in the
polylinker of pcDNA3-Tat was deleted to remove an Asp718I site for subsequent cloning purposes. This modified Tat expression vector pTat was used throughout this study. Total cellular DNA from
infected cells was isolated as described previously (11). Proviral tat sequences were amplified from total cellular
DNA by a standard 35-cycle PCR reaction by using sense primer KV1 (5'-CCATCGATACCGTCGACATAGCAGAATAGG-3') and the
antisense primer WS3 (5'-TAGAATTCTTGATCCCATAAACTGATTA-3'). The
797-bp product was cleaved at the 5' terminus with ClaI (the
recognition site in the primer is underlined) and with
Asp718I downstream of the first Tat coding exon and cloned
into pTat, thus replacing the wild-type tat gene. Several
pTat clones derived from an individual culture were sequenced to
determine the sequence variation in the virus population. Sequence
analysis was performed with a T7 DYEnamic Direct cycle sequencing kit
(Amersham) on an automated DNA sequencer (ABI). Several revertant Tat
sequences were subsequently cloned from the pTat vector into the pLAI
infectious molecular clone by exchange of a 2.6-kb
SalI-BamHI fragment. The Y47N mutation was
introduced into wild-type and F32A pTat by PCR mutagenesis (25) with mutagenic primer Y47N
(5'-CTTCTTCCTGCCATTGGAGATGCCTAA-3' [the
mismatching nucleotide is underlined]). Cloning of Y47N into the pLAI
plasmid was performed as described above. All constructs were verified
by sequence analysis.
RNA isolation and primer extension assay.
As an internal
control for primer extension analysis, we constructed a modified
LTR-CAT reporter plasmid by filling in the HindIII site
that fuses the HIV-1 LTR promoter to the cat gene, thus
creating transcripts with a 4-nucleotide (nt) insertion (LTR-CAT+4). Transfections of C33A cells for primer extension analysis contained equal amounts of LTR-CAT and LTR-CAT+4. Cells were harvested 2 days
after transfection, and total RNA was isolated by the hot phenol method
(4), ethanol precipitated, and dissolved in 20 µl of TE.
Then, 1 µl of RNA was used for primer extension analysis as described
previously (10), with some minor modifications. A new
primer, complementary to the 5' end of the cat open reading frame, was used (Sp6CATAUGrev,
5'-CGATTTAGGTGACACTATAGCTCCATTTTAGCTTCCTTAGC-3'). Reverse
transcription was performed at 42°C, and the reaction was stopped by
the addition of 1 µl of 0.5 M EDTA, denatured in the presence of
formamide, and analyzed on a 6% polyacrylamide sequencing gel. The
cDNA products were quantitated on a PhosphorImager (Molecular Dynamics).
Western blotting.
Subconfluent COS cells (60-mm dish) were
transfected with 10 µg of the Tat expression vectors by the
DEAE-dextran method. The cells were lysed in Laemmli buffer 2 days
after transfection, and the proteins were resolved on a 20% sodium
dodecyl sulfate-polyacrylamide gel. Mouse monoclonal anti-Tat antibody
4 was used to detect Tat protein in a Western blot analysis as
described previously (40).
 |
RESULTS |
Tat-mutated HIV-1 and the selection of revertant viruses.
We
previously constructed a set of Tat mutants in the HIV-1 LAI isolate
(41). Substitution of the aromatic amino acids tyrosine at
position 26 and phenylalanine at position 32 by alanine (mutants Y26A
and F32A) resulted in replication-impaired viruses. Other mutants
include a tryptophane for phenylalanine substitution at position 38 (F38W) that is reduced in Tat activity and virus growth and mutant
Y47H. Tat codon 47 (UAU) is special in that it overlaps the Rev
translation initiation codon by two nucleotides
(...UAUG...). Although the Y47H Tat protein is
partially active, virus replication is abrogated because the Rev
translation initiation codon is disrupted (...CACG...) (41). This set of four Tat
mutants was used in this study to select for revertant viruses in
prolonged cultures. Some other Tat mutants that are defective in
replication were also subjected to forced evolution, but we failed to
obtain revertant viruses. In particular, other Tat codon 47 Rev
mutants could not be reactivated except for a single
Y47H culture. Reversion of these virus mutants may be particularly
difficult because both the Tat activity and Rev expression need to be
restored. In the design of the other Tat mutants, the codon was changed such that it would be relatively difficult for the mutant virus to
revert to the wild-type amino acid. For instance, we used the alanine
codon GCC to substitute for the phenylalanine codon UUU at position 32. Reversion to the wild-type codon requires mutation of all three
nucleotides, whereas only two changes would be required if the alanine
codon GCU was used. In other words, we tried to optimize the chances of
selecting for Tat revertants with second-site mutations by restricting
the ability to generate wild-type revertants.
Forced evolution was initiated by massive transfection of the mutant
molecular clones into the SupT1 T-cell line. The cultures
were
maintained to allow virus spread until any replication-competent
variant could expand to a significant portion of the cells, as
indicated by CA-p24 production in the culture supernatant and
the
appearance of virus-induced multinucleated cells (syncytia).
Once virus
production was apparent, we passaged the cell-free
supernatant onto
uninfected SupT1 cells, initially with a large
inoculum (up to 100 µl
of supernatant), but this amount was gradually
decreased (e.g., 0.1 µl to infect 10
6 T cells in a 5-ml culture). To determine
the range of mechanisms
by which these mutant viruses could restore
replication, we attempted
to recover revertant viruses in multiple,
independent cultures
of the Y26A mutant (32 cultures), the F32A mutant
(21 cultures),
and the Y47H mutant (8 cultures). The cultures in which
we succeeded
to select for a fast-replicating HIV-1 variant are listed
in Table
1. Indicated is the original Tat
mutation, the culture number,
and the time that this evolution
experiment was maintained (in
days posttransfection). We obtained
fast-replicating virus in
a significant number of the evolution
experiments with mutant
Y26A (9 cultures) and in almost all F32A
infections (19 cultures).
Infections started with the Y47H mutant did
yield only one positive
virus culture. We also analyzed viruses in one
long-term culture
of the poorly replicating but not completely
defective F38W mutant.
Sequence analysis of revertant viruses.
The SupT1 cells of
cultures containing a replicating virus variant were harvested at the
day indicated in Table 1, and the total cellular DNA was isolated. A
portion of the integrated HIV-1 proviral genome, including the first
Tat coding exon, was amplified by PCR and cloned into the pTat
expression plasmid for sequence analysis and transient expression of
the variant Tat protein. At least two independent clones were sequenced
for each revertant to recognize mutations that may have been introduced
during PCR amplification of the proviral genome. In some cultures, Tat
sequences were analyzed at multiple times during evolution (e.g., F32A
culture A3, days 21 and 49 posttransfection; Table 1). The amino acid changes observed within the first Tat coding exon and the corresponding codon changes are listed in Table 1. In general, it is obvious that
some of the revertant viruses did not acquire any mutations in Tat, and
these viruses may have improved their replication fitness by other
means (see Discussion). We will focus below on those revertants that do
contain an additional amino acid substitution in Tat, either at the
site of mutation (first site) or at other positions (second sites).
(i) Y26A mutant.
We analyzed all nine revertant cultures of
the total of 32 infections that were started with the Y26A mutant. Five
cultures acquired a nonsilent mutation in the first Tat coding exon,
three at the first site (marked in boldface in Table 1) and two at a
second site. Thus, two putative second-site Tat revertants were obtained, Y26A-Y47N and Y26A-K50R, and both will be analyzed in further
detail below.
In the three first-site Tat revertants, the mutated A26 residue was
changed either back to the wild-type amino acid (tyrosine)
or to other
aromatic residues (phenylalanine and tryptophane).
In fact, the latter
two Tat variants were tested previously as
part of a large mutational
study (
41). Efficient LTR-CAT
trans-activation
was measured for the 26F and 26W variants (103 and 86% of the
wild-type level, respectively). Furthermore, efficient virus
replication
was demonstrated for these two variants, thus confirming
that
these changes cause the reversion phenotype. These functional
Tat
data are included in Table
1. It is interesting that relatively
difficult mutations were used to change the mutant alanine codon
GCC
into the codons for these aromatic residues, requiring three
transversions (UGG, tryptophane), one transversion and one transition
(UUC, phenylalanine), or two transversions and one transition
for the
wild-type revertant (UAU, tyrosine). Obviously, other
possible codons
could be generated by a more simple 1-nt substitution,
including codons
for threonine, serine, proline, aspartic acid,
valine, and glycine. The
absence of such nonaromatic amino acids
in the revertant cultures
suggests that these residues do not
support Tat function and viral
replication. Consistent with this
result, nonaromatic residues are not
observed at position 26 in
the Tat protein of natural HIV-1 isolates,
exception for histidine
which, like aromatic residues, has a large ring
structure (Table
2). These combined
results demonstrate the importance of an aromatic
side chain at
position 26 of the Tat protein.
(ii) F32A mutant.
It was relatively easy to improve the
fitness of the replication-impaired F32A mutant. We observed 19 reversions in a total of 21 cultures, and the corresponding viruses
were analyzed. Five revertants did not show any amino acid change in
the Tat protein. Of the remaining 14 cultures, 8 contained a first-site
change (indicated in boldface in Table 1) and a putative second-site change was detected in 6 cultures: K29R (observed three times), C27Y,
Q54R, and S70P (each observed once). Some of these changes were not
present in all of the clones that were sequenced per reversion event.
For instance, C27Y was present in only one of the two clones, and S70P
was observed in two of the four sequences (Table 1). Because Tat
changes that determine the reversion phenotype are expected to become
fixated in the virus population, these changes represent less likely
candidates for a mutation that triggered the reversion. In contrast,
the K29R mutation in culture V1 became fully fixated (10 of 10 sequences), and this mutation also appeared in two other independent
evolution experiments (cultures Z4-3 and A6 NS), suggesting that this
Tat variation represents a true revertant. The putative F32A-K29R and
F32A-Q54R second-site revertants were chosen for further analysis (see below).
Of the first-site changes of mutant F32A, we observed two mutations
back to the wild-type residue phenylalanine and six mutations
to
valine. The two wild-type revertants were generated by different
codon
changes (from GCC to
UUC and
UUU), which
demonstrates the
independent nature of these evolution experiments. The
fact that
the wild-type F32 revertant was obtained twice and that no
tryptophane
or tyrosine variants were selected at this position may
indicate
that, in contrast to position 26, other aromatic residues
cannot
replace F32. Indeed, the 32W variant was constructed previously
and demonstrated reduced Tat activity (74%), coinciding with a
substantial loss of virus fitness (
41).
It was surprising that valine was observed six times as an alternative
amino acid at position 32 because this residue is not
present in
natural isolates (Table
2). Frequent observation of
the valine
revertant may be caused in part by the relative ease
of the
corresponding nucleotide change (1-nt transition from GCC
to
G
UC). Nevertheless, it is obvious that valine should at
least
partially restore Tat activity and virus replication. Indeed,
we
measured improved transcriptional activity for the 32V revertant
compared with the 32A mutant in transient LTR-CAT assays (15 and
4% of
the wild-type Tat activity, respectively; see Table
1).
Introduction of
the 32V mutation into pLAI demonstrated that this
variation slightly
improved virus replication (Fig.
3C). We measured
previously that the
15% Tat activity is below the threshold for
efficient virus
replication (
41).
(iii) F38W and Y47H mutants.
The single revertant culture of
both the F38W and Y47H mutants was analyzed. The F38W virus maintained
the original mutation and acquired a second-site mutation at position
29. This K29R mutation, which was also observed repeatedly in the
context of the F32A mutant (see above), was present in all 12 clones
that were sequenced, indicating that this amino acid substitution was fixated in the virus population. The Y47H Tat/Rev
mutant
acquired the Q17K mutation as a putative second-site Tat adaptation,
but this mutation does not repair the Rev start codon.
Functional tests of second-site Tat mutations.
Several
putative second-site changes were observed in the Tat protein of
revertant viruses. To test which Tat changes represent true second-site
suppressor mutations, we analyzed them for recovery of Tat activity in
transient LTR-CAT transfection assays. In Fig. 1 we summarize the data of several
independent transfection experiments. Wild-type Tat activity was set at
100% (corresponding to approximately 160-fold induction of LTR
promoter activity), and the mutant and revertant Tat proteins were
tested in parallel for activation of HIV-1 gene expression. Mutant Y26A
acquired two independent second-site mutations, Y47N and K50R. Whereas
the K50R mutation did not improve the Tat activity, the Y47N mutation
increased the activity of the Y26A mutant from 7 to 23% (Fig. 1). We
also prepared Tat dose-response curves to see if the
trans-activation plateau reached with wild-type Tat can be
accomplished with this revertant protein. The Y26A-Y47N double mutant
trans-activated the HIV-1 promoter to levels exceeding the
23% activity that was measured in the linear range of
trans-activation by the wild-type Tat protein (Fig.
2B). In fact, at even higher Tat levels
we measured trans-activation levels that approximated the
wild-type trans-activation plateau (not shown). Thus,
Y26A-Y47N represents a true second-site Tat revertant. As a final test
for the reversion phenotype, we inserted the Y26A-Y47N genotype in the
pLAI molecular clone. Note that the AAU codon for
asparagine at position 47 does not disrupt the overlapping
AUG start codon of the rev gene. Indeed, Y47N was able to rescue the replication defect caused by the Y26A mutation (Fig. 3A). Thus, Y26A-Y47N is a bona fide
second-site Tat revertant that partially restores the
trans-activation function of Tat, leading to a concomitant
increase in virus fitness.

View larger version (21K):
[in this window]
[in a new window]
|
FIG. 1.
Transcriptional activity of mutant Tat proteins and
putative revertants. Cotransfections were performed with the LTR-CAT
reporter and the indicated Tat variants in the SupT1 T-cell line. The
trans-activation activity obtained with wild type was set at
100%. The results represent the average of two to eight transfection
experiments.
|
|

View larger version (11K):
[in this window]
[in a new window]
|
FIG. 2.
trans-Activation of LTR-CAT in response to
increasing amounts of Tat. We used 1 µg of LTR-CAT and 0.3, 1, 3, and
10 µg of Tat expression plasmid in transient transfections of SupT1
cells. (A) Wild-type Tat, mutant Y26A, and revertant Y26A-Y47N. (B)
Wild-type Tat, mutant F32A, and revertant F32A-K29R.
|
|

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 3.
Replication kinetics of Tat-mutated HIV-1 viruses and
revertants thereof. The SupT1 cell line was transfected with 5 µg of
the wild-type, mutant, or revertant pLAI constructs, and virus
production was measured by CA-p24 ELISA at several times
posttransfection. A slight drop in CA-p24 values was observed in some
experiments due to dilution of the culture in order to sustain cell
viability and virus replication.
|
|
Second-site mutations that were observed in the F32A virus (C27Y, K29R,
Q54R, and S70P) did not improve the level of Tat-mediated
LTR-CAT
expression (Fig.
1). This result was somewhat unexpected
because the
K29R mutation was selected in three independent reversions
of the F32A
mutant. We also tested Tat activity at various levels
of this
trans-activator protein, but no gain of function was
apparent
(Fig.
2B). Likewise, the second-site changes observed in the
F38W
and Y47H viruses (F38W-K29R and Y47H-Q17K) did not improve the
trans-activation capacity of the mutant Tat proteins (Fig.
1).
Thus, the majority of putative Tat second-site revertants,
including
Y26A-K50R, F32A-K29R, and F32A-Q54R, did not improve the Tat
activity
in LTR-CAT transcription
assays.
It remains possible that these second-site Tat mutations rescue virus
replication through an effect on another function that
Tat may have in
the HIV-1 replication cycle, e.g., in the process
of reverse
transcription (
16,
18). Thus, some of the adaptive
changes
within Tat may have been selected to improve such a nontranscriptional
function. To critically test this, some of the yet-unexplained
second-site Tat mutations were introduced into HIV-1 LAI to screen
for
improved replication in comparison with the original mutant.
However,
we did not observe increased virus replication for the
Y26A-K50R virus
(Fig.
3A) and the F32A-K29R and F32A-Q54R viruses
(Fig.
3B), ruling out
a role of these second-site changes in the
reversion
event.
The Y47N suppressor mutation functions at the transcriptional
level.
The LTR-CAT trans-activation results obtained
with the Y26A-Y47N double mutant do not discriminate between an effect
of this second-site Tat revertant at the level of transcription or
translation. To test the transcription function of the Tat revertant,
we performed direct RNA analyses on extracts of cells that were
transiently transfected with the LTR-CAT reporter construct and a Tat
expression vector. Total RNA was isolated 2 days after transfection and
used in primer extension assays (Fig. 4).
In this assay, we used equimolar amounts of the wild-type LTR-CAT
construct and a modified LTR-CAT vector with a neutral 4-nt insertion
at position +77 of the HIV-CAT fusion transcript. This control plasmid
is used as an internal standard for LTR activity in case mutant LTRs
are tested. Here, activation of both LTRs will produce a double signal
in primer extension assays. No RNA transcripts were detectable in the
absence of Tat (Fig. 4, lane 4), but a dramatic upregulation of the two LTR-CAT reporter constructs was caused by the wild-type protein (lane
1). The Y26A Tat mutant demonstrated only 7% activity of the wild-type
activity (lane 2), but this value was significantly improved to 17%
for the Y26A-Y47N revertant (lane 3). This result is consistent with
the CAT assays (Fig. 1) and indicates that this Tat revertant has
restored the transcriptional function of the Tat protein. We used
Western blot analysis (Fig. 5) to
demonstrate that the wild-type, mutant, and revertant Tat proteins are
expressed at similar levels.

View larger version (27K):
[in this window]
[in a new window]
|
FIG. 4.
Primer extension analysis of Tat-induced transcripts.
RNA was isolated from C33A cells that were transfected with two
different LTR-CAT reporter constructs (see Materials and Methods) and
wild-type Tat (lane 1), mutant Y26A (lane 2), revertant Y26A-Y47N (lane
3), or the control vector (lane 4). Indicated are the full-length cDNA
products and pause products that are due to stalling of the reverse
transcriptase enzyme.
|
|

View larger version (41K):
[in this window]
[in a new window]
|
FIG. 5.
Western blot analysis of wild-type and variant Tat
proteins. COS cells were transfected with 10 µg of the indicated Tat
expression vectors (lanes 2 to 5). Lane 1 contains a mock-transfected
COS cell sample. Total cell extracts were prepared at 2 days
posttransfection and analyzed on a Western blot that was stained with
Tat monoclonal antibody. The two Tat forms of 72 and 86 amino acids are
indicated (41). The positions of the molecular-mass marker
proteins are indicated on the left.
|
|
The Y47N mutation also improves the function of the wild-type Tat
protein.
It is of interest to test whether the Y47N mutation does
uniquely improve the function of the Y26A mutant. Such a specificity may be indicative of a direct interaction of amino acids 26 and 47 in
the three-dimensional structure of Tat. We therefore introduced the
Y47N mutation in the context of the wild-type Tat protein and the
inactive F32A mutant. Surprisingly, LTR-CAT transfections revealed that
the Y47N mutation does also improve the function of wild-type Tat to
merely 200% (Fig. 6A). Thus, the Y47N
mutation seems to improve the Tat function in a more general manner,
independent of the Y26A mutation. Western blotting demonstrated that
the Y47N Tat protein is expressed at a normal level in transfected
cells (Fig. 5). The positive effect of the Y47N change is even more striking if one considers the negative effects of many alternative amino acid substitutions that were tested previously at this position (summarized in Fig. 6B). The Y47N mutation was not able to rescue the
function of the inactive F32A mutant (Fig. 6A).

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 6.
(A) trans-Activation activity of several Tat
proteins. (A) Effect of the Y47N mutation in the context of wild-type
Tat, the Y26A mutant, and the F32A mutant. (B) Activities of several
codon 47 Tat mutants (some of the data have been published previously
([41]). Wild-type Tat activity is set at 100%.
|
|
Although the Y47N mutation improves the activity of the wild-type Tat
protein about twofold, this amino acid is not observed
in natural HIV-1
isolates (Table
2). We introduced the Y47N mutation
in the wild-type
LAI virus to test whether the viral replication
rate can be improved by
a more potent Tat
trans-activator. In
replication assays, we
repeatedly measured a small replication
disadvantage of the Y47N mutant
compared to the wild-type control
(Fig.
7).

View larger version (12K):
[in this window]
[in a new window]
|
FIG. 7.
Replication kinetics of wild-type HIV-1 and the Y47N
mutant virus. SupT1 cells were transfected with 0.5 µg (A) or 5 µg
(B) of the molecular clones. Virus replication was monitored by
measuring CA-p24 antigen production in the culture supernatant at
several days posttransfection. In panel A, the culture was split at
days 4 and 7 posttransfection, causing a small drop in the CA-p24
values.
|
|
 |
DISCUSSION |
Long-term cultures were performed with different Tat-defective
HIV-1 mutants to screen for second-site reversion events within the
tat gene. Fast-replicating virus variants were observed in 30 cultures, and we subsequently analyzed the tat gene. We
describe one Tat variant with a second-site amino acid change that
restored the activity of the mutant protein. The activity of the Y26A
Tat mutant was increased more than threefold by an additional mutation at position 47, where a tyrosine residue was replaced by asparagine (Y47N). Primer extension assays revealed that the suppressor mutation within Tat acted at the transcriptional level. It is demonstrated that
the Y47N change can rescue the replication of the Y26A mutant virus.
Thus, a tyrosine (Y47) was removed in response to mutation of another
tyrosine (Y26). This is somewhat striking because both residues are
highly conserved in natural Tat sequences, and replacement by alanine
and asparagine as seen in this study is never observed in virus
isolates (Table 2). Furthermore, a previous mutational analysis of the
wild-type Tat protein indicated that both tyrosines are important for
Tat function (41).
A surprising result was obtained when the Y47N suppressor mutation was
introduced as an individual mutation in the wild-type Tat context. This
Y47N mutant was two times more active than wild-type Tat in transient
assays, but the corresponding virus did not replicate more efficiently
than wild-type HIV-1 LAI. Apparently, increased trans-activation of the HIV-1 promoter does not increase the
viral replication capacity. Several explanations for this phenomenon can be envisaged. First, Tat function may not be limiting in HIV-1 replication, such that an improved Tat protein will not lead to a
concomitant increase in virus replication. Second, superactive Tat may
be toxic for the host cell and thereby neutralize the positive effect
on viral transcription. Third, the Y47N mutation may influence the
efficiency of Rev translation because the sequence context of the Rev
initiation codon is changed
(...UAUG...to...AAUG...). Because Rev production is delicately balanced to coordinate the expression of spliced and unspliced HIV-1 mRNA species, a slightly altered level of Rev protein will disturb this regulation
(31). The finding that the Y47N mutation does not enhance
virus fitness is consistent with the almost invariant occurrence of a
tyrosine residue at this position in natural virus isolates (Table 2). Thus, the analysis of revertant viruses may demonstrate how to improve
individual virus functions, but unwanted side effects are likely due to
the complexity of this retroviral genome.
The loss of function that is observed for the Y26A mutant may result
from aberrant folding of the mutant protein and/or from a loss of
interaction of Tat with either TAR RNA or cellular cofactors. In the
former scenario, the Y47N suppressor mutation could function to restore
the Tat protein structure. However, since the Y47N mutation also
increased the trans-activation activity of wild-type Tat, we
do not think that the putative effect on the Tat structure is specific
for the Y26A mutation. Preliminary structure-probing experiments by
limiting protease digestion of recombinant GST-Tat fusion proteins did
not reveal gross differences in the degradation pattern of the
wild-type Tat protein, the Y26A mutant, and the Y26A-Y47N revertant
(results not shown). It is not likely that TAR RNA binding is affected
by the Y26A mutation, since the RNA-binding domain of Tat localizes to
the basic domain (positions 49 to 57 [38]). However,
it remains possible that the Y47N suppressor mutation, which is
positioned close to the RNA-binding domain, could enhance TAR RNA
binding of the Y26A mutant (and wild-type Tat). We performed
electrophoretic mobility shift assays to study the TAR RNA interaction
of the mutant and revertant Tat proteins, but no difference was
observed (results not shown). Thus, we currently have no molecular
explanation for the Y47N reversion event, but it is most likely that
this amino acid change does influence the interaction of Tat with
cellular cofactors, e.g., the PTEF-b or TFIIH complexes (15, 19,
23, 42, 45) or the Sp1 transcription factor (9, 20).
The mechanism of action of the Y47N suppressor mutation is not specific
for the SupT1 cells used in these experiments because the same results
were obtained in the C33A cell line (results not shown).
Other second-site changes observed in the Tat protein of revertant
viruses did not contribute to Tat function but could theoretically improve secondary functions of Tat in the virus life cycle and thus
rescue virus replication. We therefore tested several putative second-site revertants in virus replication assays, but no increase in
replication capacity was apparent. Thus, no evidence for a role of Tat
in processes other than transcription was found. In general, these
results underscore the notion that the Tat trans-activation function closely parallels the viral replication rate (41). It is most likely that these second-site Tat mutations represent spontaneous sequence variation within the HIV-1 genome that became fixated in some of these long-term infection experiments. Fixation of
the new sequences is possible by nonrandom sampling effects during
passage of the crippled mutants (bottleneck passage or founder effect).
Alternatively, these fixated mutations may represent "bystander
mutations" that were linked to another mutation that did improve
replication and which formed the target for selection. Such a random
genetic linkage is unlikely to explain the K29R mutation, which was
observed three times in independent F32A reversions and in the F38W
revertant. It is possible that this particular mutation represents a
frequent Tat variation. Consistent with this idea is the fact that both
basic amino acids are present in natural HIV-1 isolates (7/56 R, 40/56
K [Table 2]). Similarly, some of the other Tat changes that do not
represent true second-site revertants are observed frequently in
natural isolates (e.g., Q54R 5/56).
We do not understand how the Y47H virus has gained replication capacity
since this particular mutant is also Rev defective. The fixated
second-site Tat mutation Q17K seems unable to restore Rev expression,
but analysis of the more important second coding exon of Rev in the
revertant virus may provide more information. Alternatively, this
revertant virus may actually represent a Rev-independent HIV-1 variant.
These possibilities are currently under investigation.
A surprising result of this evolution study with Tat-mutated viruses is
that virus replication can apparently be restored by changes that map
outside the Tat first coding exon. This is not only the case for
revertant viruses that do not contain compensatory mutations within Tat
but also true for Tat proteins with second-site mutations that do not
improve virus fitness. We cannot exclude that suppressor mutations are
present in the second Tat coding exon that encodes the C-terminal 14 amino acids. However, we do not expect such mutations in this part of
the protein, since the C terminus of Tat contributes only marginally to
virus replication (28, 39). It would seem, a priori, to be
possible to repair a defect in the Tat transcriptional activator by
second-site changes in the LTR promoter. In particular, one would
expect LTR changes that improve the basal promoter activity, thus
rendering the virus less dependent on Tat. We have described such an
LTR adaptation in the culture with the Y26A-Y47N Tat revertant
(41a). It is also possible that improvement of other,
unrelated viral functions can partially restore the replication of
Tat-mutated viruses. For instance, we reported recently that a
translation-impaired HIV-1 mutant can dramatically improve its
replication by optimizing the mechanistically unrelated Env function
(12). This example underscores the notion that the outcome
of virus evolution studies can sometimes be very complex and yet intriguing.
One could argue that the forced-evolution approach used here for the
recovery of spontaneous revertant viruses is not very effective, since
only one true second-site Tat revertant was obtained from 30 cultures
that harbored a fast-replicating virus revertant. However, we did
isolate 11 first-site Tat revertants, and some were generated by
relatively difficult types of mutation (e.g., multiple transversions).
These results suggest that there may be very few single amino acid
changes at secondary sites that can render the Tat mutants active. This
finding suggests the importance of specific residues at these
positions, and these amino acids may be involved in interactions with
cellular cofactors or the TAR RNA element. Alternatively, these amino
acids may be required to form the specific tertiary structure of the
Tat activation domain. In this scenario, the conformation apparently
cannot be restored by any amino acid change elsewhere in the protein.
In addition, the presence of overlapping reading frames (vpr
or rev) and RNA signals (splice acceptors or splicing
silencers [1]) may put additional constraints on the
evolutionary flexibility of the tat gene (28).
Thus, the evolutionary approach may not be an efficient method to study
structure-function relationships in small proteins with a high
information density. Obviously, we cannot exclude the possibility that
the activity of these Tat mutants can be restored by multiple amino
acid changes at secondary sites, but the probability of finding such
hypermutated variants is remote. Perhaps the virus evolution experiment
can benefit from strategies to introduce random mutations within the
gene under selection (24, 35). Alternatively, part of the
tat gene can be provided as a randomized nucleotide sequence
(5), such that the search for second-site revertants will
occur in a much broader section of sequence space. A major disadvantage
of these approaches is that a significant fraction of viral genomes
that are manipulated in this way will contain additional mutations that
interfere with virus replication.
The forced-evolution approach should be applicable to other virus
genes, and perhaps larger proteins and enzymes are more amenable to
second-site repair (37, 43). We and others demonstrated previously that this approach is ideally suited for studying RNA elements, in particular structured motifs that play critical roles in
virus replication (6, 21, 29, 30). The enormous genetic flexibility of structured RNA motifs is due to the fact that completely different sequences can form very similar base-pair structures. The
relative inflexibility of the Tat protein may make it an excellent target for the development of potent anti-HIV drugs.
 |
ACKNOWLEDGMENTS |
We thank Wim van Est for assistance in preparation of the
figures, Benjamin Rowland for assistance with the TAR-RNA binding and
protease digestion assays, Jeroen van Wamel for the Western blot
analysis, and Tamara Prinsenberg and Rogier Sanders for help with
sequence analysis and LTR-CAT transfections. Christine Debouck kindly
provided anti-Tat reagents.
This study was supported in part by the Dutch AIDS Foundation, an EMBO
short-term fellowship (K.V.), and the European Community (EU 950675).
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Human Retrovirology, Academic Medical Center, University of Amsterdam, Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands. Phone:
31-20-5664822. Fax: 31-20-6916531. E-mail:
b.berkhout{at}amc.uva.nl.
 |
REFERENCES |
| 1.
|
Amendt, B. A.,
Z. Si, and C. M. Stolzfus.
1995.
Presence of exon splicing silencers within human immunodeficiency virus type 1 tat exon 2 and tat-rev exon 3: evidence for inhibition mediated by cellular factors.
Mol. Cell. Biol.
15:4606-4615[Abstract].
|
| 2.
|
Back, N. K. T.,
M. Nijhuis,
W. Keulen,
C. A. B. Boucher,
B. B. Oude Essink,
A. B. P. van Kuilenburg,
A. H. Van Gennip, and B. Berkhout.
1996.
Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.
EMBO J.
15:4040-4049[Medline].
|
| 3.
|
Bayer, P.,
M. Kraft,
A. Ejchart,
M. Westendorp,
R. Frank, and P. Rosch.
1995.
Structural studies of HIV-1 Tat protein.
J. Mol. Biol.
247:529-535[Medline].
|
| 3a.
| Berkhout, B., and A. T. Das. Functional analysis of
RNA signals in the HIV-1 genome by forced evolution. In J. Barciszewski and B. F. C. Clark (ed.), RNA biochemistry and
biotechnology, in press. Kluwer Academic Publishers, Dordrecht, The
Netherlands.
|
| 4.
|
Berkhout, B.,
A. Gatignol,
J. Silver, and K. T. Jeang.
1990.
Efficient trans-activation by the HIV-2 Tat protein requires a duplicated TAR RNA structure.
Nucleic Acids Res.
18:1839-1846[Abstract/Free Full Text].
|
| 5.
|
Berkhout, B., and B. Klaver.
1993.
In vivo selection of randomly mutated retroviral genomes.
Nucleic Acids Res.
21:5020-5024[Abstract/Free Full Text].
|
| 6.
|
Berkhout, B.,
B. Klaver, and A. T. Das.
1997.
Forced evolution of a regulatory RNA helix in the HIV-1 genome.
Nucleic Acids Res.
25:940-947[Abstract/Free Full Text].
|
| 7.
|
Berkhout, B.,
R. H. Silverman, and K. T. Jeang.
1989.
Tat trans-activates the human immunodeficiency virus through a nascent RNA target.
Cell
59:273-282[Medline].
|
| 8.
|
Braddock, M.,
A. M. Thorburn,
A. Chambers,
G. D. Elliot,
G. J. Anderson,
A. J. Kingsman, and S. M. Kingsman.
1990.
A nuclear translational block imposed by the HIV-1 U3 region is relieved by the Tat-TAR interaction.
Cell
62:1123-1133[Medline].
|
| 9.
|
Chun, R. F.,
O. J. Semmes,
C. Neuveut, and K.-T. Jeang.
1998.
Modulation of Sp1 phosphorylation by human immunodeficiency virus type 1 Tat.
J. Virol.
72:2615-2629[Abstract/Free Full Text].
|
| 10.
|
Das, A. T.,
B. Klaver, and B. Berkhout.
1995.
Reduced replication of human immunodeficiency virus type 1 mutants that use reverse transcription primers other than the natural tRNA3Lys.
J. Virol.
69:3090-3097[Abstract].
|
| 11.
|
Das, A. T.,
B. Klaver,
B. I. F. Klasens,
J. L. B. van Wamel, and B. Berkhout.
1997.
A conserved hairpin motif in the R-U5 region of the human immunodeficiency virus type 1 RNA genome is essential for replication.
J. Virol.
71:2346-2356[Abstract].
|
| 12.
|
Das, A. T.,
A. P. van Dam,
B. Klaver, and B. Berkhout.
1998.
Improved envelope function selected by long-term cultivation of a translation-impaired HIV-1 mutant.
Virology
244:552-562[Medline].
|
| 13.
|
Dingwall, C.,
I. Ernberg,
M. J. Gait,
S. M. Green,
S. Heaphy,
J. Karn,
A. D. Lowe,
M. Singh,
M. A. Skinner, and R. Valerio.
1989.
Human immunodeficiency virus 1 tat protein binds trans-activating-responsive region (TAR) RNA in vitro.
Proc. Natl. Acad. Sci. USA
86:6925-6929[Abstract/Free Full Text].
|
| 14.
|
Freund, J.,
L. Vertesy,
K. P. Koller,
V. Wolber,
D. Heintz, and H. R. Kalbitzer.
1995.
Complete 1H nuclear magnetic resonance assignments and structural characterization of a fusion protein of the alpha-amylase inhibitor tendamistat with the activation domain of the human immunodeficiency virus type 1 Tat protein.
J. Mol. Biol.
250:672-688[Medline].
|
| 15.
|
Garcia-Martinez, L. F.,
G. Mavankal,
J. M. Neveu,
W. S. Lane,
D. Ivanov, and R. B. Gaynor.
1997.
Purification of a Tat-associated kinase reveals a TFIIH complex that modulates HIV-1 transcription.
EMBO J.
16:2836-2850[Medline].
|
| 16.
|
Harrich, D.,
C. Ulich,
L. F. Garcia-Martinez, and R. B. Gaynor.
1997.
Tat is required for efficient HIV-1 reverse transcription.
EMBO J.
16:1224-1235[Medline].
|
| 17.
|
Hauber, J.,
M. Malim, and B. Cullen.
1989.
Mutational analysis of the conserved basic domain of human immunodeficiency virus Tat protein.
J. Virol.
63:1181-1187[Abstract/Free Full Text].
|
| 18.
|
Huang, L. M.,
A. Joshi,
R. Willey,
J. Orenstein, and K. T. Jeang.
1994.
Human immunodeficiency viruses regulated by alternative trans-activators: genetic evidence for a novel non-transcriptional function of Tat in virion infectivity.
EMBO J.
13:2886-2896[Medline].
|
| 19.
|
Jeang, K.-T.
1998.
Tat, Tat-associated kinase, and transcription.
J. Biomed. Sci.
5:24-27[Medline].
|
| 20.
|
Jeang, K. T.,
R. Chun,
N. H. Lin,
A. Gatignol,
C. G. Glabe, and H. Fan.
1993.
In vitro and in vivo binding of human immunodeficiency virus type 1 Tat protein and Sp1 transcription factor.
J. Virol.
67:6224-6233[Abstract/Free Full Text].
|
| 21.
|
Klaver, B., and B. Berkhout.
1994.
Evolution of a disrupted TAR RNA hairpin structure in the HIV-1 virus.
EMBO J.
13:2650-2659[Medline].
|
| 22.
|
Kuppuswamy, M.,
T. Subramanian,
A. Srinivasan, and G. Chinnadurai.
1989.
Multiple functional domains of Tat, the trans-activator of HIV-1, defined by mutational analysis.
Nucleic Acids Res.
17:3551-3561[Abstract/Free Full Text].
|
| 23.
|
Mancebo, H. S. Y.,
G. Lee,
J. Flygare,
J. Tomassini,
P. Luu,
Y. Zhu,
J. Peng,
C. Blau,
D. Hazuda,
D. Price, and O. Flores.
1997.
P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro.
Genes Dev.
11:2633-2644[Abstract/Free Full Text].
|
| 24.
|
Martinez, M. A.,
J. P. Vartanian, and S. Wain-Hobson.
1994.
Hypermutagenesis of RNA using human immunodeficiency virus type 1 reverse transcriptase and biased dNTP concentrations.
Proc. Natl. Acad. Sci. USA
91:11787-11791[Abstract/Free Full Text].
|
| 25.
|
Mikaelian, I., and A. Sergeant.
1992.
A general and fast method to generate multiple site-directed mutations.
Nucleic Acids Res.
20:376[Free Full Text].
|
| 26.
|
Mujeeb, A.,
K. Bishop,
B. M. Peterlin,
C. Turck,
T. G. Parslow, and T. L. James.
1994.
NMR structure of a biologically active peptide containing the RNA-binding domain of human immunodeficiency virus type 1 Tat.
Proc. Natl. Acad. Sci. USA
91:8248-8252[Abstract/Free Full Text].
|
| 27.
|
Myers, G.,
S. Wain-Hobson,
L. E. Henderson,
B. Korber,
K. T. Jeang, and G. N. Pavlakis.
1994.
Human retroviruses and AIDS 1994. A compilation and analysis of nucleic acid and amino acid sequences. Theoretical biology and biophysics.
Los Alamos National Laboratory, Los Alamos, N.M.
|
| 28.
|
Neuveut, C., and K.-T. Jeang.
1996.
Recombinant human immunodeficiency virus type 1 genomes with Tat unconstrained by overlapping reading frames reveal residues in Tat important for replication in tissue culture.
J. Virol.
70:5572-5581[Abstract/Free Full Text].
|
| 29.
|
Olsthoorn, R. C. L.,
N. Licis, and J. van Duin.
1994.
Leeway and constraints in the forced evolution of a regulatory RNA helix.
EMBO J.
13:2660-2668[Medline].
|
| 30.
|
Olsthoorn, R. C. L., and J. van Duin.
1996.
Evolutionary reconstruction of a hairpin deleted from the genome of an RNA virus.
Proc. Natl. Acad. Sci. USA
93:12256-12261[Abstract/Free Full Text].
|
| 31.
|
Rabson, A. B., and B. J. Graves.
1997.
Synthesis and processing of viral RNA, p. 205-262.
In
J. M. Coffin, S. H. Hughes, and H. E. Varmus (ed.), Retroviruses. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
| 32.
|
Seed, B., and J. Y. Sheen.
1988.
A simple phase-extraction assay for chloramphenicol acyltransferase activity.
Gene
67:271-277[Medline].
|
| 33.
|
Seigel, L. J.,
L. Ratner,
S. F. Josephs,
D. Derse,
M. B. Feinberg,
G. R. Reyes,
S. J. O'Brien, and F. Wong-Staal.
1986.
Trans-activation induced by human T-lymphotrophic virus type III (HTLV-III) maps to a viral sequence encoding 58 amino acids and lacks tissue specificity.
Virology
148:226-231[Medline].
|
| 34.
|
SenGupta, D. N.,
B. Berkhout,
A. Gatignol,
A. M. Zhou, and R. H. Silverman.
1990.
Direct evidence for translational regulation by leader RNA and Tat protein of human immunodeficiency virus type 1.
Proc. Natl. Acad. Sci. USA
87:7492-7496[Abstract/Free Full Text].
|
| 35.
|
Siderovski, D. P.,
T. Matsuyama,
E. Frigerio,
S. Chui,
X. Min,
H. Erfle,
M. Sumner Smith,
R. W. Barnett, and T. W. Mak.
1992.
Random mutagenesis of the human immunodeficiency virus type-1 trans-activator of transcription (HIV-1 Tat).
Nucleic Acids Res.
20:5311-5320[Abstract/Free Full Text].
|
| 36.
|
Silverman, R. H., and D. N. SenGupta.
1990.
Translational regulation by HIV leader RNA, TAT, and interferon-inducible enzymes.
J. Exp. Pathol.
5:69-77[Medline].
|
| 37.
|
Taddeo, B.,
F. Carlini,
P. Verani, and A. Engelman.
1996.
Reversion of a human immunodeficiency virus type 1 integrase mutant at a second site restores enzyme function and virus infectivity.
J. Virol.
70:8277-8284[Abstract].
|
| 38.
|
Tan, R.,
A. Brodsky,
J. R. Williamson, and A. D. Frankel.
1997.
RNA recognition by HIV-1 Tat and Rev.
Semin. Virol.
8:186-193.
|
| 39.
|
Verhoef, K.,
M. Bauer,
A. Meyerhans, and B. Berkhout.
1998.
On the role of the second coding exon of the HIV-1 Tat protein in virus replication and MHC class 1 downregulation.
AIDS Res. Hum. Retroviruses
14:1553-1559[Medline].
|
| 40.
|
Verhoef, K.,
A. Klein, and B. Berkhout.
1996.
Paracrine activation of the HIV-1 LTR promoter by the viral Tat protein is mechanistically similar to trans-activation within a cell.
Virology
225:316-327[Medline].
|
| 41.
|
Verhoef, K.,
M. Koper, and B. Berkhout.
1997.
Determination of the minimal amount of Tat activity required for human immunodeficiency virus type 1 replication.
Virology
237:228-236[Medline].
|
| 41a.
|
Verhoef, K.,
R. W. Sanders,
V. Fontaine,
S. Kitajima, and B. Berkhout.
1999.
Evolution of the human immunodeficiency virus type 1 long terminal repeat promoter by conversion of an NF- B enhancer element into a GABP binding site.
J. Virol.
73:1331-1340[Abstract/Free Full Text].
|
| 42.
|
Wei, P.,
M. E. Garber,
S.-M. Fang,
W. H. Fisher, and K. A. Jones.
1998.
A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA.
Cell
92:451-462[Medline].
|
| 43.
|
Willey, R. L.,
E. K. Ross,
A. J. Buckler-White,
T. S. Theodore, and M. A. Martin.
1989.
Functional interaction of constant and variable domains of human immunodeficiency virus type gp120.
J. Virol.
63:3595-3600[Abstract/Free Full Text].
|
| 44.
|
Xiao, H.,
C. Neuveut,
M. Benkirane, and K.-T. Jeang.
1998.
Interaction of the second coding exon of Tat with human EF-1 delta delineates a mechanism for HIV-1-mediated shut-off of host mRNA translation.
Biochem. Biophys. Res. Commun.
17:384-389.
|
| 45.
|
Yang, X.,
M. O. Gold,
D. N. Tang,
D. E. Lewis,
E. Aguilar-Cordova,
A. P. Rice, and C. H. Herrmann.
1997.
TAK, an HIV Tat-associated kinase, is a member of the cyclin-dependent family of protein kinases and is induced by activation of peripheral blood lymphocytes and differentiation of promonocytic cell lines.
Proc. Natl. Acad. Sci. USA
94:12331-12336[Abstract/Free Full Text].
|
Journal of Virology, April 1999, p. 2781-2789, Vol. 73, No. 4
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Hidalgo-Estevez, A. M., Gonzalez, E., Punzon, C., Fresno, M.
(2006). Human immunodeficiency virus type 1 Tat increases cooperation between AP-1 and NFAT transcription factors in T cells. J. Gen. Virol.
87: 1603-1612
[Abstract]
[Full Text]
-
Ammosova, T., Jerebtsova, M., Beullens, M., Lesage, B., Jackson, A., Kashanchi, F., Southerland, W., Gordeuk, V. R., Bollen, M., Nekhai, S.
(2005). Nuclear Targeting of Protein Phosphatase-1 by HIV-1 Tat Protein. J. Biol. Chem.
280: 36364-36371
[Abstract]
[Full Text]
-
Xie, B., Calabro, V., Wainberg, M. A., Frankel, A. D.
(2004). Selection of TAR RNA-Binding Chameleon Peptides by Using a Retroviral Replication System. J. Virol.
78: 1456-1463
[Abstract]
[Full Text]
-
Ammosova, T., Jerebtsova, M., Beullens, M., Voloshin, Y., Ray, P. E., Kumar, A., Bollen, M., Nekhai, S.
(2003). Nuclear Protein Phosphatase-1 Regulates HIV-1 Transcription. J. Biol. Chem.
278: 32189-32194
[Abstract]
[Full Text]
-
Reza, S. M., Shen, L.-M., Mukhopadhyay, R., Rosetti, M., Pe'ery, T., Mathews, M. B.
(2003). A Naturally Occurring Substitution in Human Immunodeficiency Virus Tat Increases Expression of the Viral Genome. J. Virol.
77: 8602-8606
[Abstract]
[Full Text]
-
Xie, B., Wainberg, M. A., Frankel, A. D.
(2003). Replication of Human Immunodeficiency Viruses Engineered with Heterologous Tat-Transactivation Response Element Interactions. J. Virol.
77: 1984-1991
[Abstract]
[Full Text]
-
Verhoef, K., Bilodeau, P. S., van Wamel, J. L. B., Kjems, J., Stoltzfus, C. M., Berkhout, B.
(2001). Repair of a Rev-Minus Human Immunodeficiency Virus Type 1 Mutant by Activation of a Cryptic Splice Site. J. Virol.
75: 3495-3500
[Abstract]
[Full Text]
-
Verhoef, K., Marzio, G., Hillen, W., Bujard, H., Berkhout, B.
(2001). Strict Control of Human Immunodeficiency Virus Type 1 Replication by a Genetic Switch: Tet for Tat. J. Virol.
75: 979-987
[Abstract]
[Full Text]
-
Jeang, K.-T., Xiao, H., Rich, E. A.
(1999). Multifaceted Activities of the HIV-1 Transactivator of Transcription, Tat. J. Biol. Chem.
274: 28837-28840
[Full Text]